Table 2.

Clinical, endoscopic, and histological characteristics and clinical course of patients with CPI-associated gastritis.

Patient	Endoscopic features	Histopathological features	Treatment for ir-gastritis	Subsequent therapies	Autoimmune side effects after re-challenge
1	Moderate pangastritis	Lymphocytes Plasma cells Granulocytes Erosive mucosa 17 apoptoses/10 HPF	Pantoprazole 40 mg 2×/day Prednisolone 1 mg/kg bw	Dabrafenib plus trametinib	No re-challenge with CPI
2	Severe erosive pangastritis	Lymphocytes Plasma cells Granulocytes 4 apoptoses/10 HPF	Pantoprazole 40 mg 2×/day Prednisolone 1 mg/kg bw	Nivolumab plus relatlimab	No immune-related adverse events
3	Severe erythematous pangastritis	Lymphocytes Plasma cells Granulocytes Ulcerations 6 apoptoses/10 HPF	Pantoprazole 40 mg 2×/day Prednisolone 1 mg/kg bw	Pembrolizumab plus domatinostat	No immune-related adverse events
4	Severe pangastritis, separation of the gastric mucosa	Lymphocytes Plasma cells Granulocytes 14 apoptoses/10 HPF	Dexamethasone 8 mg Metoclopramide 10 mg 2×/day Pantoprazole 40 mg 2×/day	Nivolumab	No immune-related adverse events
5	Severe hemorrhagic pangastritis	Lymphocytes Plasma cells Granulocytes Intestinal metaplasia 3 apoptoses/10 HPF	Pantoprazole 40 mg 2×/day Prednisolone 1 mg/kg bw	Nivolumab Binimetinib plus encorafenib	No immune-related adverse events

CPI, checkpoint inhibition; ir, immune-related. bw, bodyweight; HPF, high power field.